Bioprocessing - Upstream & Downstream

ADCs have suffered a few setbacks over the years, but interest in their therapeutic potential – particularly against cancer – remains high.

Innovation in glass continues to be a key enabler for allowing pharma manufacturers to make better, safer products for patients.

Early collaboration and open communication between upstream and downstream are crucial to ensure a consistent end-to-end bioprocess.

Gene is in charge of seed train duty! But the reality doesn’t quite live up to his expectations…

What lies ahead for Gene and Eva in 2019? Cell and gene therapies!

It’s time for pharma to leave behind the highly energy-dependent and inflexible processes of the 20th century. Let’s “biologicalize” manufacturing.

The stem cell industry needs to embrace bioprocess control systems to develop consistent, high quality, and commercially viable bioprocesses.

Intensifying or simplifying your bioprocess can mean more product, shorter manufacturing times, or lower costs.

Single-pass TFF is a convenient means of reducing volumes, column sizes and hardware costs, as well as eliminating tank bottlenecks...

The 2018 Innovation Awards are here! From capsules, to software, to high-tech mass spectrometers; we celebrate the advances of the field.